Latest data from the Hong Kong Stock Exchange reveals that on April 15, HHLR Advisors, Ltd. purchased an additional 26.2 million shares of CStone PHARMA-B (02616). The transaction was executed at a price of HK$8.97 per share, amounting to a total investment of approximately HK$235 million. Following this acquisition, HHLR Advisors' total shareholding in the company has increased to 88.6645 million shares, representing a 6.01% stake.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.